Cereno Scientific broadens patent protection for drug candidate CS585 and strengthens its future commercial position in the US
Cereno Scientific (XSAT: CRNO B) today announced that a patent has been allowed in the second patent family for the preclinical Prostacyclin Receptor Agonist Program, which includes drug candidate CS585. The patent broadens the intellectual property rights (IPR) for CS585 in the US – a large market in cardiovascular disease. CS585 is currently in a preclinical development program in collaboration with the University of Michigan with the target to submit the application (IND) to initiate a Phase I study in 2023.“This is a great milestone for our preclinical Prostacyclin Receptor Agonist